Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: akoyabio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $7.00 → $5.00 | Buy → Hold | Craig Hallum |
| 8/6/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/6/2024 | Buy → Neutral | BTIG Research | |
| 8/6/2024 | Overweight → Neutral | JP Morgan | |
| 6/21/2024 | $7.50 | Buy | Craig Hallum |
| 12/14/2023 | Neutral | Guggenheim | |
| 7/5/2023 | $18.00 | Overweight | JP Morgan |
| 2/2/2023 | $14.00 | Buy | UBS |
| 11/3/2022 | $19.00 | Overweight | CapitalOne |
| 10/6/2022 | $16.00 | Overweight | Stephens |
Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously
Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight
BTIG Research downgraded Akoya Biosciences from Buy to Neutral
JP Morgan downgraded Akoya Biosciences from Overweight to Neutral
Craig Hallum initiated coverage of Akoya Biosciences with a rating of Buy and set a new price target of $7.50
Guggenheim initiated coverage of Akoya Biosciences with a rating of Neutral
JP Morgan resumed coverage of Akoya Biosciences with a rating of Overweight and set a new price target of $18.00
UBS initiated coverage of Akoya Biosciences with a rating of Buy and set a new price target of $14.00
CapitalOne initiated coverage of Akoya Biosciences with a rating of Overweight and set a new price target of $19.00
Stephens initiated coverage of Akoya Biosciences with a rating of Overweight and set a new price target of $16.00
10-Q - Akoya Biosciences, Inc. (0001711933) (Filer)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
8-K - Akoya Biosciences, Inc. (0001711933) (Filer)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
SCHEDULE 13D/A - Akoya Biosciences, Inc. (0001711933) (Filed by)
SCHEDULE 13D/A - Akoya Biosciences, Inc. (0001711933) (Subject)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
8-K - Akoya Biosciences, Inc. (0001711933) (Filer)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
10-K/A - Akoya Biosciences, Inc. (0001711933) (Filer)
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we
It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat
Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, and Enable Medicine, a real-world data company providing AI-ready patient, cellular and molecular data, today announced a groundbreaking collaboration to deliver the largest commercially available single-cell spatial proteomics atlas to the research and clinical community. Enable Medicine's Pan-Cancer Atlas is a unique multi-modal dataset built using Akoya's PhenoCycler®-Fusion (PCF) platform and includes the PhenoCode™ Discovery IO60 panel as its foundational data. The Enable Atlas comprises over 100 million single cells, spanning 8,500+ samples and 15+ cancer typ
MARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA), The Spatial Biology Company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (ADC) development in breast cancer. The new assay will be featured alongside customer-generated real-world data from the PhenoCode™ Discovery IO60 panel—Akoya's flagship ultrahigh-plex immuno-oncology solution—at the American Association for Cancer Research (AACR) 2025 Annual Meeting, taking place April 25–30 in Chicago, Illinois. New ADC Assay: Advancing Breast Cancer Precision The emergence of HER2- and TROP2-targeting ADCs—such as those used in the DESTINY, ASCENT, and TRO
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore's public healthcare and research institutions in the translational cancer research ecosystem, comprising the National Cancer Centre Singapore (NCCS), National University Cancer Institute, Singapore (NCIS), National University Hospital (NUH), National University of Singapore (NUS), Singapore General Hospital (SGH) and the Agency for Science, Technology and Research (A*STAR). The partnership between Akoya Biosciences and STCC will leverage Akoya Biosciences' Phe
Urges Shareholders to Vote AGAINST Both Proposals Related to the Value-Destructive Merger with Akoya at the Upcoming Special Meeting Notes Deeply Unfair Merger is Effectively a Bailout for Akoya at the Expense of Quanterix Shareholders Outlines Concerns Around Fundamentally Flawed Transaction Process and Conflicts of Interest Among Quanterix Board Members Visit www.SaveQTRX.com to Learn How to Vote the GOLD Proxy Card and Preserve Quanterix's Clear and Compelling Path Toward Long-Term Value Creation Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today announced that it
Tikvah Management LLC (together with its affiliates, "Tikvah" or "we"), which owns approximately 1.5% of the outstanding common shares of Quanterix Corp. ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued a statement calling on the Company to explain its most recent purchase agreement for up to $30 million in convertible notes from Akoya Biosciences, Inc. ("Akoya") (NASDAQ:AKYA). Tikvah's statement follows: "This announcement concerns us for several reasons. First, we believe Akoya's need to obtain bridge financing serves as a significant warning sign of its financial distress. Second, we find it both unusual and coercive to Quanterix's shareholders that this capital is being comm
Disturbed that Quanterix Is Apparently Moving Forward with One of the Most Shareholder Unfriendly Aspects of Merger Agreement with Akoya Encourages Shareholders to Vote AGAINST Both Proposals Related to Approval of the Transaction Kent Lake PR LLC ("Kent Lake") is a holder of approximately 7.5% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX). Today, Kent Lake issued a statement related to recent disclosures indicating that Quanterix has officially entered into a Securities Purchase Agreement under which Akoya Biosciences ("Akoya") (NASDAQ:AKYA) has the ability to sell the Company up to $30 million in convertible notes. Kent Lake has p
Akoya's technology to generate data for a first-of-its-kind Biobank and Data Repository for Cancer Equity Research, funded through the Cancer Grand Challenges initiative The unprecedented scale of the initiative requires the high plex and high throughput of Akoya's PhenoCycler-Fusion platform to process thousands of patients' samples MARLBOROUGH, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, and SAMBAI, a team funded through the Cancer Grand Challenges initiative, today announced that Akoya's PhenoCycler-Fusion system will be the foundational spatial proteomics technology used to generate data for a first-of-its-kind Bioba
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13D/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13D/A - Akoya Biosciences, Inc. (0001711933) (Subject)
Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ
MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the
MARLBOROUGH, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Marilee Moy as Chief People Officer. Ms. Moy has more than 30 years of HR leadership experience at high-performing life sciences and technology companies. She will be instrumental in defining and executing Akoya's human resource strategy as the company enters a new phase of global growth. Ms. Moy joins Akoya with deep operational and strategic expertise in managing human resources for rapidly growing life sciences companies. She has worked at life sciences and technology companies ranging from start-ups to international,
MARLBOROUGH, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Pascal Bamford, PhD, as Senior Vice President, Research and Development and Laboratory Operations. Dr. Bamford will be instrumental in accelerating the innovation of ground-breaking spatial biology solutions and the scaling of Akoya's Advanced Biopharma Services (ABS) offering. Dr. Bamford joins Akoya with deep scientific and operational experience, leading teams in developing and implementing successful and innovative products and shepherding them through international regulatory agencies to reach customers and patients wo
MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true pioneer and leader in the diagnostic industry, to its board of directors. "It is an honor to join the board of Akoya, a company that is providing innovative spatial biology solutions with the potential to transform the life sciences market," said Dr. Lai-Goldman. "Akoya's platforms provide an unprecedented capability to understand the relationship of cells to their tumor microenvironment, and span applications from discovery and clinical research. The groundbreaking discoveries emanating from t
MARLBOROUGH, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of diagnostics industry leader Scott Mendel to its board of directors. "I am delighted to join the board of directors of Akoya, a company that has the potential to transform biomarker discovery and clinical research through the application of its spatial biology platforms," Mr. Mendel said. "Akoya's cutting-edge solutions enable scientists to visualize how cells are organized and interact within the tissue microenvironment, providing unprecedented understanding of disease progression and treatment response." Mr. Mendel is currently CEO
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i
Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose temporary challenges. We proactively anticipated this with our recent organizational restructuring, which, while difficult and temporarily disruptive this quarter, was the right decision and en
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at https://investors.akoyabio.com/. About A
MARLBOROUGH, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the second quarter ending June 30, 2024. "Our second-quarter revenue showed a strong rebound with 26% sequential top-line growth and a stable year-over-year performance," said Brian McKelligon, CEO of Akoya Biosciences. "We believe that Akoya's platforms are poised to lead the spatial biology market from discovery to diagnostics, while we also position the company to achieve near-term operating cash flow breakeven as we align our cost structure with our strategic objectives." Second Quarter 2024 Financial and Bu
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at https://investors.akoyabio.com/. Akoya also announced that management will b
MARLBOROUGH, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2024. Business Highlights Revenue was $18.4 million in the first quarter of 2024, compared to $21.4 million in the prior year period; a decrease of 14%. Reagents and services revenue continued to increase.Akoya announced the establishment of a new Manufacturing Center of Excellence in Marlborough, Massachusetts to scale internal reagent manufacturing to meet the accelerating demand for reagents.Akoya's partner Acrivon Therapeutics presented initial positive Phase 2b clinical
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the "Investors" section of the Akoya website at https://investors.akoyabio.com/. About Akoya Biosciences
Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. "Akoya's successful 2023 performance reflects the high demand for our leading spatial biology solutions and effective execution of our financial and strategic plan," said Brian McKelligon, CEO of Akoya Biosciences. "We expanded our installed base to nearly 1,200 instruments, improved platform speeds,